GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Asset Turnover

Abbott Laboratories (Abbott Laboratories) Asset Turnover

: 0.14 (As of Dec. 2023)
View and export this data going back to 1949. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Abbott Laboratories's Revenue for the three months ended in Dec. 2023 was $10,241 Mil. Abbott Laboratories's Total Assets for the quarter that ended in Dec. 2023 was $72,652 Mil. Therefore, Abbott Laboratories's Asset Turnover for the quarter that ended in Dec. 2023 was 0.14.

Asset Turnover is linked to ROE % through Du Pont Formula. Abbott Laboratories's annualized ROE % for the quarter that ended in Dec. 2023 was 16.76%. It is also linked to ROA % through Du Pont Formula. Abbott Laboratories's annualized ROA % for the quarter that ended in Dec. 2023 was 8.78%.


Abbott Laboratories Asset Turnover Historical Data

The historical data trend for Abbott Laboratories's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.49 0.58 0.58 0.54

Abbott Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.13 0.14 0.14 0.14

Competitive Comparison

For the Medical Devices subindustry, Abbott Laboratories's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories Asset Turnover Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Asset Turnover falls into.



Abbott Laboratories Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Abbott Laboratories's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=40109/( (74438+73214)/ 2 )
=40109/73826
=0.54

Abbott Laboratories's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=10241/( (72090+73214)/ 2 )
=10241/72652
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Abbott Laboratories  (NYSE:ABT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Abbott Laboratories's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=6376/38042
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(6376 / 40964)*(40964 / 72652)*(72652/ 38042)
=Net Margin %*Asset Turnover*Equity Multiplier
=15.56 %*0.5638*1.9098
=ROA %*Equity Multiplier
=8.78 %*1.9098
=16.76 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Abbott Laboratories's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=6376/72652
=(Net Income / Revenue)*(Revenue / Total Assets)
=(6376 / 40964)*(40964 / 72652)
=Net Margin %*Asset Turnover
=15.56 %*0.5638
=8.78 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Abbott Laboratories Asset Turnover Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q2 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024